The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Multidimensional analysis of B7 homolog 3 (B7-H3) RNA expression in small-cell lung cancer (SCLC) molecular subtypes.
 
Carl Michael Gay
Honoraria - American Society for Radiation Oncology; Aptitude Health; Daiichi Sankyo Nordics; DAVA Pharmaceuticals; Peerview; Targeted Oncology
Consulting or Advisory Role - Abdera Therapeutics; AstraZeneca; Catalyst Pharmaceuticals; G1 Therapeutics; Jazz Pharmaceuticals; Monte Rosa Therapeutics; Pharmerit
Research Funding - AstraZeneca
Patents, Royalties, Other Intellectual Property - US-20240011103-A1 MOLECULAR SUBTYPING OF SMALL CELL LUNG CANCER TO PREDICT THERAPEUTIC RESPONSES
Travel, Accommodations, Expenses - American Society for Radiation Oncology; Dava Oncology; ESMO; IASLC; MJH Live Events; Roche/Genentech
 
Taofeek K. Owonikoko
Stock and Other Ownership Interests - CAMBIUM MEDICAL TECHNOLOGIES; Coherus Biosciences; GenCart; Taobob LLC
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; BeiGene; BerGenBio; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Coherus Biosciences; Daichi; Eisai; Eisai; EMD Serono; Exelixis; G1 Therapeutics; Heat Biologics; Ipsen; Janssen; Jazz Pharmaceuticals; Lilly; MedImmune; Merck; Meryx Pharmaceuticals; Novartis; PharmaMar; Puma Biotechnology; Roche/Genentech; Takeda; Triptych Health Partners; Xcovery
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Corvus Pharmaceuticals; G1 Therapeutics (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Loxo/Lilly (Inst); Merck (Inst); Meryx Pharmaceuticals (Inst); Novartis (Inst); Oncorus (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - DR4 Modulation and its Implications in EGFR-Target Cancer Therapy Ref:18089 PROV (CSP) United States Patent Application No. 62/670,210 June 26, 2018 (Co-Inventor) (Inst); OVERCOMING ACQUIRED RESISTANCE TO CHEMOTHERAPY TREATMENTS THROUGH SUPPRESSION OF STAT3 (Inst); SELECTIVE CHEMOTHERAPY TREATMENTS AND DIAGNOSTIC METHODS RELATED THERETO (Inst); Soluble FAS ligand as a biomarker of recurrence in thyroid cancer; provisional patent 61/727,519 (Inventor) (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen
Other Relationship - EMD Serono; Novartis; Roche/Genentech
(OPTIONAL) Uncompensated Relationships - Reflexion Medical
 
Lauren Averett Byers
Honoraria - Clinical Care Options; UpToDate
Consulting or Advisory Role - Abbvie; Amgen; Arrowhead Pharmaceuticals; AstraZeneca; BeiGene; Chugai Pharma; Daiichi Sankyo; Genentech; Jazz Pharmaceuticals; Merck Sharp & Dohme Corp.; Puma Biotechnology
Research Funding - Amgen (Inst); AstraZeneca (Inst); Jazz Pharmaceuticals (Inst)
 
Noura J. Choudhury
Consulting or Advisory Role - Abbvie; G1 Therapeutics; Harpoon therapeutics; Sanofi
Research Funding - Abbvie (Inst); Amgen (Inst); Harpoon therapeutics (Inst); Merck (Inst); Monte Rosa Therapeutics (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from Wolters Kluwer (Pocket Oncology).
 
Sajid Ahmed
Employment - D&iichi Sankyo, Inc
Stock and Other Ownership Interests - Day One Biopharmaceuticals; Pfizer
 
Zachary Cain
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Xiaozhong Qian
Employment - Daiichi Sankyo
 
Matthew Brentnall
Employment - Caris Life Sciences
 
Simon Heeke
Employment - Marker Therapeutics (I)
Honoraria - Qiagen
Consulting or Advisory Role - Boehringer Ingelheim
Speakers' Bureau - AstraZeneca; Guardant Health
Patents, Royalties, Other Intellectual Property - Patent on the Treatment of Lung Cancer
Travel, Accommodations, Expenses - Roche
 
Ming Poi
Employment - Caris Life Sciences
Stock and Other Ownership Interests - BridgeBio Pharma; Bristol-Myers Squibb/Celgene; Novartis; Pfizer
 
Sharon Wu
Employment - Caris Life Sciences
Research Funding - Caris Life Sciences
 
Charles M. Rudin
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Auron Therapeutics; Bridge Medicines; D2G Oncology; Daiichi Sankyo/UCB Japan; DISCO; Earli; Genentech/Roche; Harpoon Therapeutics; Jazz Pharmaceuticals; Kowa; Merck
Research Funding - Daiichi Sankyo (Inst); Merck (Inst); Roche/Genentech (Inst)